US Bancorp
COGT icon

US Bancorp’s Cogent Biosciences COGT Stock Holding History

US Bancorp’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$449K Sell
11,612
-598
-5% -$20.9K ﹤0.01% 1644
2026
Q1 		$470K Buy
12,210
+12,052
+7,628% +$445K ﹤0.01% 1542
2025
Q4 		$5.61K Buy
+158
New +$4.44K ﹤0.01% 3492
2025
Q3 		– Sell
-31
Closed -$223 – 4065
2025
Q2 		$223 Sell
31
-195
-86% -$1.08K ﹤0.01% 4070
2025
Q1 		$1.35K Buy
+226
New +$1.77K ﹤0.01% 3940
2024
Q3 		– Sell
-137
Closed -$1.16K – 4099
2024
Q2 		$1.16K Buy
+137
New +$1.04K ﹤0.01% 3793
2023
Q4 		– Sell
-245
Closed -$2.39K – 4001
2023
Q3 		$2.39K Sell
245
-188
-43% -$2.23K ﹤0.01% 3617
2023
Q2 		$5.13K Sell
433
-2,811
-87% -$32.3K ﹤0.01% 3469
2023
Q1 		$35K Sell
3,244
-498
-13% -$6.37K ﹤0.01% 2695
2022
Q4 		$43.3K Buy
3,742
+1,518
+68% +$18.8K ﹤0.01% 2613
2022
Q3 		$33K Buy
2,224
+923
+71% +$12.7K ﹤0.01% 2768
2022
Q2 		$12K Buy
+1,301
New +$8.88K ﹤0.01% 3293
2021
Q3 		– Sell
-61
Closed – – 4091
2021
Q2 		$0 Buy
+61
New +$515 ﹤0.01% 4009

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

US Bancorp's COGT Position: Q2 2026 in Review

US Bancorp reduced its Cogent Biosciences (COGT) stake by 4.9% in Q2 2026, selling an estimated $20.9K and leaving 11,612 shares worth $449K. The position accounts for ﹤0.01% of the portfolio, ranked #1644.

US Bancorp first reported a position in COGT in Q2 2021 and has held it in 13 quarters since. The position peaked at $470K in Q1 2026. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • US Bancorp held 11,612 shares of Cogent Biosciences worth $449K as of Q2 2026.
  • US Bancorp sold 598 Cogent Biosciences shares in Q2 2026, an estimated $20.9K.
  • Cogent Biosciences made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1644 holding.
  • US Bancorp first reported a position in Cogent Biosciences in Q2 2021 and has held it in 13 quarters since.
  • US Bancorp's Cogent Biosciences position peaked at $470K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.